Glucagon-Like Peptide 1 receptor agonists and chronic lower respiratory disease exacerbations among patients with Type 2 diabetes

Analysis of US claims data (n=16,690) found GLP-1RA users had fewer chronic lower respiratory disease (CLRD) exacerbations vs DPP-4I users, adjusted incident rate of first CLRD admission 10.7 vs 20.3 per 1000 person-years (adjusted HR 0.52, 95% CI 0.32–0.85).

Source:

Diabetes Care